ALB and diabetic kidney disease: A trial of 123 subjects with stage 3 CKD and the Effect of Topiroxostat on Urinary albumin in hyperuricemic patients with Diabetic nEphropathy (ETUDE) trial found topiroxostat reduced urinary albumin-creatinine ratio (UACR) (Hosoya et al., 2014; Mizukoshi et al., 2018).